The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events

Medicine and Dentistry

• Imipramine 100%
• Breast Cancer 62%
• DNA Repair 50%
• Cancer Growth 37%
• Patient 37%
• Estrogen Receptor 25%
• Malignant Neoplasm 25%
• Cell Cycle 25%
• Combination Therapy 25%
• Estrogen Receptor Positive Breast Cancer 25%
• Antidepressant 25%
• Cell DNA 25%
• DNA Repair Protein 25%
• Growth 25%
• Triple Negative Breast Cancer 25%
• Protein 12%
• Ex Vivo 12%
• Cyclin D1 12%
• Cell Cycle Arrest 12%
• Homologous Recombination 12%
• Antiestrogen 12%
• Drug 12%
• Chemotherapeutic Agent 12%
• Non-Homologous End Joining 12%
• PARP Inhibitor 12%
• Olaparib 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Imipramine 100%
• Breast Cancer 62%
• Cancer Growth 37%
• Clinical Trial 37%
• Estrogen Receptor Positive Breast Cancer 25%
• Malignant Neoplasm 25%
• Triple Negative Breast Cancer 25%
• Protein 12%
• Mouse Model 12%
• Antiestrogen 12%
• Drug 12%
• Cyclin D1 12%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor 12%
• Olaparib 12%

Biochemistry, Genetics and Molecular Biology

• Estrogen Receptor 50%
• DNA Repair 50%
• Growth 50%
• Cell Cycle 25%
• Homologous Recombination 12%
• Cyclin D1 12%
• Explant 12%
• Mouse Model 12%
• Non-Homologous End Joining 12%
• RAD51 12%
• Cell Cycle Arrest 12%
• E2F1 12%
• Poly ADP Ribose Polymerase 12%
• Protein 12%